Teriparatide

What is Teriparatide?

Teriparatide is a recombinant form of the first 34 amino acids of human parathyroid hormone (PTH 1-34). Unlike most osteoporosis drugs that only slow bone loss, teriparatide is anabolic — it actually stimulates new bone formation. It is FDA-approved for treatment of osteoporosis in patients at high fracture risk.

What Teriparatide Is Investigated For

Teriparatide is investigated and FDA-approved for severe osteoporosis at high fracture risk — postmenopausal women, men with primary or hypogonadal osteoporosis, and patients on chronic glucocorticoids — with additional off-label use for stress fracture healing. The strongest evidence is the pivotal Neer et al. Fracture Prevention Trial (NEJM 2001), which showed a 65% reduction in vertebral fractures and 53% reduction in non-vertebral fractures over a median 19 months, supported by a deep subsequent meta-analysis literature comparing teriparatide favorably against bisphosphonates and denosumab. Teriparatide is unusual among osteoporosis drugs in being anabolic — it actively builds bone via pulsatile PTH1R signaling — rather than antiresorptive. The honest caveats: the original black-box osteosarcoma warning based on rat carcinogenicity was removed by FDA in 2020 after 20+ years of negative human surveillance, but baseline-risk contraindications (Paget's, prior bone radiation, open epiphyses) remain. BMD gains are rapidly lost after discontinuation unless a bisphosphonate or denosumab consolidation phase follows, and daily-injection adherence is moderate at best in real-world cohorts.

History & Discovery

The therapeutic insight underlying teriparatide is decades old: continuous parathyroid hormone exposure (as in primary hyperparathyroidism) leaches calcium from bone and causes osteopenia, but intermittent pulsatile PTH exposure has the opposite effect — it preferentially stimulates osteoblast activity and produces a net anabolic gain in bone mass. This 'paradox of PTH' was characterized in the 1980s and 1990s in animal and small human studies. The recombinant 1–34 fragment of human PTH (the N-terminal portion containing receptor-binding activity) was developed by Eli Lilly as a daily subcutaneous injection that mimics the pulsatile pharmacology required for the anabolic effect. The pivotal Phase 3 Fracture Prevention Trial (Neer et al., New England Journal of Medicine 2001) randomized over 1,600 postmenopausal women with prior vertebral fracture and demonstrated a 65% reduction in new vertebral fractures and a 53% reduction in non-vertebral fractures over a median 19-month treatment duration. The trial was halted early when carcinogenicity studies in Fischer 344 rats showed dose- and duration-dependent osteosarcoma development at high lifetime exposures. FDA approval in November 2002 came with a black box warning for osteosarcoma risk and a 24-month lifetime use restriction. Subsequent post-marketing surveillance over more than two decades — including the Forteo Patient Registry — has not identified an osteosarcoma signal in human use; the FDA removed the black box warning and the 24-month lifetime use restriction in 2020 based on accumulated evidence. Forteo became one of Lilly's flagship endocrinology products and shaped the entire anabolic osteoporosis category, with abaloparatide (Tymlos, 2017) and the sclerostin inhibitor romosozumab (Evenity, 2019) building on the anabolic concept. A first biosimilar PTH(1–34), Bonsity, was approved in 2019.

How It Works

When given in daily pulses, teriparatide stimulates the bone-building cells (osteoblasts) to create new bone faster than the bone-breaking cells (osteoclasts) can remove it. This net gain in bone mass reduces fracture risk.

Intermittent (pulsatile) PTH 1-34 administration preferentially stimulates osteoblast activity over osteoclast activity, creating an 'anabolic window.' It binds the PTH1 receptor on osteoblasts, activating cAMP/PKA and Wnt/beta-catenin signaling, promoting osteoblast proliferation, differentiation, and survival while inhibiting sclerostin. Continuous PTH exposure has the opposite effect (catabolic), which is why daily injection timing is critical.

Evidence Snapshot

Research Gaps & Open Questions

What the current literature has not yet settled about Teriparatide:

• 01Optimal sequencing relative to romosozumab and abaloparatide — the modern anabolic landscape now includes three distinct agents (PTH analog, PTHrP analog, sclerostin inhibitor); head-to-head sequencing trials are limited and treatment-algorithm consensus is evolving.
• 02Long-term human osteosarcoma signal — over 20 years of post-marketing surveillance has not identified an osteosarcoma excess in treated patients, supporting the FDA's 2020 removal of the black box warning. However, the very long latency for solid-tumor signals means continued pharmacovigilance is warranted.
• 03Repeat-course efficacy — patients who complete a course, transition to antiresorptive consolidation, and are later considered for a second teriparatide course are an under-studied population. Limited data suggest a second course produces modest additional BMD gains.
• 04Real-world adherence and persistence — daily injection therapy adherence is moderate at best in real-world cohorts; predictors of adherence and interventions to improve persistence are incompletely characterized.
• 05Combination with antiresorptive therapy (concurrent rather than sequential) — most concurrent-therapy trials have shown attenuation of the anabolic effect, but specific combinations and timing windows might allow synergy; this remains an active research area.
• 06Use in atypical femoral fracture and bisphosphonate-related osteonecrosis of the jaw — observational data suggest benefit, but adequately powered trials in these specific complications are limited.

Forms & Administration

Daily subcutaneous injection of 20mcg. Self-administered via pen device. Treatment limited to 2 years. All injectable peptides should only be administered under the guidance of a qualified healthcare provider. Never self-administer without clinician oversight.

Dosing & Protocols

The ranges below reflect protocols commonly discussed in the literature and by clinicians — not a prescription. Actual dosing for any individual should be determined by a qualified healthcare provider who knows the patient.

Teriparatide is FDA-approved for postmenopausal women with osteoporosis at high fracture risk, men with primary or hypogonadal osteoporosis at high fracture risk, and patients on chronic glucocorticoid therapy at high fracture risk. It should be prescribed by a clinician experienced in osteoporosis management.

Timeline of Effects

Common Questions

Who Teriparatide Is NOT For

Drug & Supplement Interactions

Teriparatide has a relatively simple drug-interaction profile because peptide proteolytic clearance does not engage CYP-mediated metabolism. The clinically important interactions are pharmacodynamic rather than pharmacokinetic. Digoxin: theoretical concern about additive arrhythmia risk from the transient hypercalcemia produced by teriparatide; clinical significance is modest but warrants attention in patients on digoxin with established cardiac disease. Loop and thiazide diuretics: thiazides reduce urinary calcium excretion and can compound the transient post-dose hypercalcemia of teriparatide; clinical monitoring of serum calcium in patients on combined therapy is appropriate. Loop diuretics tend to increase calcium excretion and partially counteract the effect. Glucocorticoids: corticosteroids antagonize the anabolic effect of teriparatide through suppression of osteoblast activity; teriparatide is nonetheless one of the most effective agents in glucocorticoid-induced osteoporosis (with a specific FDA indication) because the magnitude of the anabolic effect outweighs the glucocorticoid-driven suppression. Bisphosphonates and denosumab: when used concurrently with teriparatide (rather than sequentially), the anabolic effect is partially blunted — concurrent use is not standard practice. Sequential use (teriparatide first, then bisphosphonate or denosumab) is the established and preferred approach. Initiating teriparatide in a patient on chronic bisphosphonate therapy may produce a smaller initial BMD response than in a treatment-naive patient, though benefit is still observed. Calcium and vitamin D: routinely co-administered as supportive care rather than an interacting drug. As with all chronic osteoporosis therapy, all medications including OTC supplements should be disclosed to the prescribing clinician.

Safety Profile

Legal Status

Regulatory status changes over time. Verify current local rules with a qualified professional.

Myths & Misconceptions